Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
Phase 3
Completed
- Conditions
- Persistent Nonvalvular Atrial Fibrillation
- Registration Number
- NCT00171769
- Lead Sponsor
- Novartis
- Brief Summary
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- persistent AF (electrical cardioversion is planned)
- written informed consent
Exclusion Criteria
- acute clinical signs of venous thromboembolism
- current oral anticoagulation
- indication for medical cardioversion
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety measures including reporting of serious adverse events and adverse events, including vascular and neurological events
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States